{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:15:00Z","timestamp":1771456500746,"version":"3.50.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"China-Japan Friendship Hospital Fund","award":["2019-1-QN-52"],"award-info":[{"award-number":["2019-1-QN-52"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>IGHV mutation status is a crucial prognostic biomarker for CLL. In the present study, we investigated the transcriptomic signatures associating with IGHV mutation status and CLL prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The co-expression modules and hub genes correlating with IGHV status, were identified using the GSE28654, by \u2018WGCNA\u2019 package and R software (version 4.0.2). The over-representation analysis was performed to reveal enriched cell pathways for genes of correlating modules. Then 9 external cohorts were used to validate the correlation of hub genes expression with IGHV status or clinical features (treatment response, transformation to Richter syndrome, etc.). Moreover, to elucidate the significance of hub genes on disease course and prognosis of CLL patients, the Kaplan\u2013Meier analysis for the OS and TTFT of were performed between subgroups dichotomized by the median expression value of individual hub genes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>2 co-expression modules and 9 hub genes ((FCRL1\/FCRL2\/HELQ\/EGR3LPL\/LDOC1\/ZNF667\/SOWAHC\/SEPTIN10) correlating with IGHV status were identified by WGCNA, and validated by external datasets. The modules were found to be enriched in NF-kappaB, HIF-1 and other important pathways, involving cell proliferation and apoptosis. The expression of hub genes was revealed to be significantly different, not only between CLL and normal B cell, but also between various types of lymphoid neoplasms. HELQ expression was found to be related with response of immunochemotherapy treatment significantly (p\u2009=\u20090.0413), while HELQ and ZNF667 were expressed differently between stable CLL and Richter syndrome patients (p\u2009&lt;\u20090.0001 and p\u2009=\u20090.0278, respectively). By survival analysis of subgroups, EGR3 expression was indicated to be significantly associated with TTFT by 2 independent cohorts (GSE39671, p\u2009=\u20090.0311; GSE22762, p\u2009=\u20090.0135). While the expression of HELQ and EGR3 was found to be associated with OS (p\u2009=\u20090.0291 and 0.0114 respectively).The Kras, Hedgehog and IL6-JAK-STAT3 pathways were found to be associating with the expression of hub genes, resulting from GSEA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The expression of HELQ and EGR3 were correlated with IGHV mutation status in CLL patients. Additionally, the expression of HELQ\/EGR3 were prognostic markers for CLL associating with targetable cell signaling pathways.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-021-02708-6","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T08:02:59Z","timestamp":1611388979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia"],"prefix":"10.1186","volume":"19","author":[{"given":"Chao","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-qian","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6623-1683","authenticated-orcid":false,"given":"Zhen-ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"issue":"11","key":"2708_CR1","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ajh.25595","volume":"94","author":"M Hallek","year":"2019","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266\u201387.","journal-title":"Am J Hematol"},{"key":"2708_CR2","doi-asserted-by":"crossref","unstructured":"International CLLIPIwg: An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6):779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"issue":"6","key":"2708_CR3","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848\u201354.","journal-title":"Blood"},{"issue":"4","key":"2708_CR4","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","volume":"100","author":"A Krober","year":"2002","unstructured":"Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, Dohner H, Stilgenbauer S. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410\u20136.","journal-title":"Blood"},{"issue":"3","key":"2708_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/bjh.16042","volume":"187","author":"B Hu","year":"2019","unstructured":"Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, et al. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019;187(3):307\u201318.","journal-title":"Br J Haematol"},{"issue":"16","key":"2708_CR6","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","volume":"126","author":"D Rossi","year":"2015","unstructured":"Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921\u20134.","journal-title":"Blood"},{"issue":"1","key":"2708_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/CBM-2012-0259","volume":"11","author":"A Trojani","year":"2011","unstructured":"Trojani A, Di Camillo B, Tedeschi A, Lodola M, Montesano S, Ricci F, Vismara E, Greco A, Veronese S, Orlacchio A, et al. Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia. Cancer Biomark. 2011;11(1):15\u201328.","journal-title":"Cancer Biomark"},{"issue":"1","key":"2708_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajh.23340","volume":"88","author":"S Fabris","year":"2013","unstructured":"Fabris S, Mosca L, Cutrona G, Lionetti M, Agnelli L, Ciceri G, Barbieri M, Maura F, Matis S, Colombo M, et al. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol. 2013;88(1):24\u201331.","journal-title":"Am J Hematol"},{"issue":"11","key":"2708_CR9","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.3109\/10428194.2015.1028051","volume":"56","author":"F Maura","year":"2015","unstructured":"Maura F, Cutrona G, Mosca L, Matis S, Lionetti M, Fabris S, Agnelli L, Colombo M, Massucco C, Ferracin M, et al. Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(11):3150\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2708_CR10","doi-asserted-by":"publisher","first-page":"e0118801","DOI":"10.1371\/journal.pone.0118801","volume":"10","author":"F Maura","year":"2015","unstructured":"Maura F, Mosca L, Fabris S, Cutrona G, Matis S, Lionetti M, Agnelli L, Barbieri M, D\u2019Anca M, Manzoni M, et al. Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. PLoS ONE. 2015;10(3):e0118801.","journal-title":"PLoS ONE"},{"issue":"21","key":"2708_CR11","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1158\/1078-0432.CCR-13-0622","volume":"19","author":"F Morabito","year":"2013","unstructured":"Morabito F, Mosca L, Cutrona G, Agnelli L, Tuana G, Ferracin M, Zagatti B, Lionetti M, Fabris S, Maura F, et al. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res. 2013;19(21):5890\u2013900.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2708_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/gcc.20579","volume":"47","author":"S Fabris","year":"2008","unstructured":"Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, et al. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2008;47(9):781\u201393.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2708_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1182\/blood-2013-12-538975","volume":"124","author":"M Weisser","year":"2014","unstructured":"Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, et al. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood. 2014;124(3):420\u20135.","journal-title":"Blood"},{"issue":"22","key":"2708_CR14","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-09-1132","volume":"15","author":"DR Friedman","year":"2009","unstructured":"Friedman DR, Weinberg JB, Barry WT, Goodman BK, Volkheimer AD, Bond KM, Chen Y, Jiang N, Moore JO, Gockerman JP, et al. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res. 2009;15(22):6947\u201355.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2708_CR15","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2012-03-416461","volume":"120","author":"HY Chuang","year":"2012","unstructured":"Chuang HY, Rassenti L, Salcedo M, Licon K, Kohlmann A, Haferlach T, Foa R, Ideker T, Kipps TJ. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012;120(13):2639\u201349.","journal-title":"Blood"},{"issue":"8","key":"2708_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3109\/10428194.2012.753445","volume":"54","author":"T Herold","year":"2013","unstructured":"Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, et al. High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leuk Lymphoma. 2013;54(8):1652\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2708_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 2008;9:559.","journal-title":"BMC Bioinf"},{"issue":"21","key":"2708_CR18","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1093\/bioinformatics\/btq522","volume":"26","author":"K Pentchev","year":"2010","unstructured":"Pentchev K, Ono K, Herwig R, Ideker T, Kamburov A. Evidence mining and novelty assessment of protein-protein interactions with the ConsensusPathDB plugin for Cytoscape. Bioinformatics. 2010;26(21):2796\u20137.","journal-title":"Bioinformatics"},{"issue":"1","key":"2708_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25\u20139.","journal-title":"Nat Genet"},{"key":"2708_CR20","doi-asserted-by":"crossref","unstructured":"The Gene Ontology C. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(1):D330\u2013D338.","DOI":"10.1093\/nar\/gky1055"},{"issue":"1","key":"2708_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","volume":"27","author":"H Ogata","year":"1999","unstructured":"Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999;27(1):29\u201334.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2708_CR22","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457-462.","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"2708_CR23","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1182\/blood-2011-03-344374","volume":"118","author":"C Gomez-Abad","year":"2011","unstructured":"Gomez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, Gonzalez-Menchen A, Martinez-Climent JA, Mata E, Rodriguez ME, Munoz-Gonzalez G, Sanchez-Beato M, et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood. 2011;118(20):5517\u201327.","journal-title":"Blood"},{"issue":"1","key":"2708_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/path.5060","volume":"245","author":"MJ Garcia-Barchino","year":"2018","unstructured":"Garcia-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, et al. Richter transformation driven by Epstein\u2013Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. J Pathol. 2018;245(1):61\u201373.","journal-title":"J Pathol"},{"issue":"43","key":"2708_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2708_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267\u201373.","journal-title":"Nat Genet"},{"issue":"2","key":"2708_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/1389202911314020005","volume":"14","author":"H Dweep","year":"2013","unstructured":"Dweep H, Sticht C, Gretz N. In-silico algorithms for the screening of possible microRNA binding sites and their interactions. Curr Genomics. 2013;14(2):127\u201336.","journal-title":"Curr Genomics"},{"issue":"2","key":"2708_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ygyno.2018.03.006","volume":"149","author":"J Long","year":"2018","unstructured":"Long J, Zhu JY, Liu YB, Fu K, Tian Y, Li PY, Yang WQ, Yang SY, Yin JY, Yin G, et al. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer. Gynecol Oncol. 2018;149(2):341\u20139.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"2708_CR29","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2015-01-623645","volume":"126","author":"H Cheng","year":"2015","unstructured":"Cheng H, Hao S, Liu Y, Pang Y, Ma S, Dong F, Xu J, Zheng G, Li S, Yuan W, et al. Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood. 2015;126(11):1302\u201313.","journal-title":"Blood"},{"issue":"36","key":"2708_CR30","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1038\/s41388-020-01418-5","volume":"39","author":"SH Shin","year":"2020","unstructured":"Shin SH, Kim I, Lee JE, Lee M, Park JW. Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer. Oncogene. 2020;39(36):5839\u201354.","journal-title":"Oncogene"},{"issue":"12","key":"2708_CR31","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41419-019-2171-3","volume":"10","author":"Z Dong","year":"2019","unstructured":"Dong Z, Li S, Wu X, Niu Y, Liang X, Yang L, Guo Y, Shen S, Liang J, Guo W. Aberrant hypermethylation-mediated downregulation of antisense lncRNA ZNF667-AS1 and its sense gene ZNF667 correlate with progression and prognosis of esophageal squamous cell carcinoma. Cell Death Dis. 2019;10(12):930.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2708_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12929-019-0506-0","volume":"26","author":"W Meng","year":"2019","unstructured":"Meng W, Cui W, Zhao L, Chi W, Cao H, Wang B. Aberrant methylation and downregulation of ZNF667-AS1 and ZNF667 promote the malignant progression of laryngeal squamous cell carcinoma. J Biomed Sci. 2019;26(1):13.","journal-title":"J Biomed Sci"},{"issue":"10","key":"2708_CR33","doi-asserted-by":"publisher","first-page":"18763","DOI":"10.1002\/jcp.28515","volume":"234","author":"Z Yang","year":"2019","unstructured":"Yang Z, Liu A, Xiong Q, Xue Y, Liu F, Zeng S, Zhang Z, Li Y, Sun Y, Xu C. Prognostic value of differentially methylated gene profiles in bladder cancer. J Cell Physiol. 2019;234(10):18763\u201372.","journal-title":"J Cell Physiol"},{"issue":"3","key":"2708_CR34","first-page":"1285","volume":"21","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Wang J, Zhang Q, Wang F, Fang L, Song B, Xie C, Liu J. Methylationdriven genes PMPCAP1, SOWAHC and ZNF454 as potential prognostic biomarkers in lung squamous cell carcinoma. Mol Med Rep. 2020;21(3):1285\u201395.","journal-title":"Mol Med Rep"},{"key":"2708_CR35","doi-asserted-by":"publisher","first-page":"103211","DOI":"10.1016\/j.jbi.2019.103211","volume":"95","author":"A Tsanousa","year":"2019","unstructured":"Tsanousa A, Ntoufa S, Papakonstantinou N, Stamatopoulos K, Angelis L. Study of gene expressions\u2019 correlation structures in subgroups of Chronic Lymphocytic Leukemia Patients. J Biomed Inform. 2019;95:103211.","journal-title":"J Biomed Inform"},{"key":"2708_CR36","doi-asserted-by":"crossref","unstructured":"Prieto D, Seija N, Uriepero A, Souto-Padron T, Oliver C, Irigoin V, Guillermo C, Navarrete MA, Ines Landoni A, Dighiero G, et al. LPL protein in chronic lymphocytic leukaemia have different origins in mutated and unmutated patients. Advances for a new prognostic marker in CLL. Br J Haematol. 2018;182(4):521\u20135.","DOI":"10.1111\/bjh.15427"},{"issue":"8","key":"2708_CR37","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.leukres.2015.05.005","volume":"39","author":"F Morabito","year":"2015","unstructured":"Morabito F, Cutrona G, Mosca L, D\u2019Anca M, Matis S, Gentile M, Vigna E, Colombo M, Recchia AG, Bossio S, et al. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. Leuk Res. 2015;39(8):840\u20135.","journal-title":"Leuk Res"},{"issue":"14","key":"2708_CR38","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1073\/pnas.1503587112","volume":"112","author":"JS Blachly","year":"2015","unstructured":"Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, et al. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015;112(14):4322\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5586","key":"2708_CR39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1126\/science.1073374","volume":"297","author":"E Ravasz","year":"2002","unstructured":"Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabasi AL. Hierarchical organization of modularity in metabolic networks. Science. 2002;297(5586):1551\u20135.","journal-title":"Science"},{"key":"2708_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2202\/1544-6115.1128","volume":"4","author":"B Zhang","year":"2005","unstructured":"Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:17.","journal-title":"Stat Appl Genet Mol Biol."},{"issue":"1","key":"2708_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1172\/JCI93801","volume":"128","author":"S Dietrich","year":"2018","unstructured":"Dietrich S, Oles M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hullein J, da Silva LM, Walther T, et al. Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2018;128(1):427\u201345.","journal-title":"J Clin Invest"},{"issue":"20","key":"2708_CR42","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1128\/MCB.23.20.7329-7338.2003","volume":"23","author":"K Takenaka","year":"2003","unstructured":"Takenaka K, Fukami K, Otsuki M, Nakamura Y, Kataoka Y, Wada M, Tsuji K, Nishikawa S, Yoshida N, Takenawa T. Role of phospholipase C-L2, a novel phospholipase C-like protein that lacks lipase activity. B-cell receptor signaling. Mol Cell Biol. 2003;23(20):7329\u201338.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2708_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1182\/blood-2008-01-131359","volume":"112","author":"FJ Li","year":"2008","unstructured":"Li FJ, Ding S, Pan J, Shakhmatov MA, Kashentseva E, Wu J, Li Y, Soong SJ, Chiorazzi N, Davis RS. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood. 2008;112(1):179\u201387.","journal-title":"Blood"},{"issue":"9","key":"2708_CR44","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.4049\/jimmunol.0901982","volume":"183","author":"Y Kochi","year":"2009","unstructured":"Kochi Y, Myouzen K, Yamada R, Suzuki A, Kurosaki T, Nakamura Y, Yamamoto K. FCRL3, an autoimmune susceptibility gene, has inhibitory potential on B-cell receptor-mediated signaling. J Immunol. 2009;183(9):5502\u201310.","journal-title":"J Immunol"},{"issue":"2","key":"2708_CR45","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10238-019-00551-0","volume":"19","author":"G Daniele","year":"2019","unstructured":"Daniele G, Abbate A, Turchiano A, Palumbo O, Carella M, Lo Cunsolo C, Iuzzolino P, Lonoce A, Hernandez-Sanchez M, Minoia C, et al. 1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia. Clin Exp Med. 2019;19(2):261\u20137.","journal-title":"Clin Exp Med"},{"issue":"4","key":"2708_CR46","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","volume":"164","author":"RR Furman","year":"2000","unstructured":"Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164(4):2200\u20136.","journal-title":"J Immunol"},{"issue":"8","key":"2708_CR47","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","volume":"18","author":"S Cuni","year":"2004","unstructured":"Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, Ballester S, Garcia-Marco J, Jorda J, Durantez A. A sustained activation of PI3K\/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18(8):1391\u2013400.","journal-title":"Leukemia"},{"issue":"4","key":"2708_CR48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1541-7786.MCR-10-0559","volume":"9","author":"Z Liu","year":"2011","unstructured":"Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z. STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Mol Cancer Res. 2011;9(4):507\u201315.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"2708_CR49","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","volume":"111","author":"S Hewamana","year":"2008","unstructured":"Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008;111(9):4681\u20139.","journal-title":"Blood"},{"issue":"13","key":"2708_CR50","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1182\/blood.2019001366","volume":"134","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF 2nd, Messer K, et al. Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-kappaB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084\u201394.","journal-title":"Blood"},{"issue":"16","key":"2708_CR51","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood-2015-07-657056","volume":"127","author":"R Valsecchi","year":"2016","unstructured":"Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C, Scarfo L, Bertilaccio MT, Brambilla P, Lenti E, et al. HIF-1alpha regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood. 2016;127(16):1987\u201397.","journal-title":"Blood"},{"issue":"4","key":"2708_CR52","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3324\/haematol.2019.217430","volume":"105","author":"V Griggio","year":"2020","unstructured":"Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Bo MD, Magliulo D, Rossi D, et al. HIF-1alpha is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica. 2020;105(4):1042\u201354.","journal-title":"Haematologica"},{"issue":"9","key":"2708_CR53","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1182\/blood-2002-07-2339","volume":"101","author":"C Campas","year":"2003","unstructured":"Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D, Gil J. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood. 2003;101(9):3674\u201380.","journal-title":"Blood"},{"issue":"4","key":"2708_CR54","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/13543781003703694","volume":"19","author":"E Van Den Neste","year":"2010","unstructured":"Van Den Neste E, Van den Berghe G, Bontemps F. AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. Expert Opin Investig Drugs. 2010;19(4):571\u20138.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"2708_CR55","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/emboj.2011.12","volume":"30","author":"DG Hardie","year":"2011","unstructured":"Hardie DG. AMPK and autophagy get connected. EMBO J. 2011;30(4):634\u20135.","journal-title":"EMBO J"},{"issue":"2","key":"2708_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/bjh.14859","volume":"179","author":"CM Stellrecht","year":"2017","unstructured":"Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol. 2017;179(2):266\u201371.","journal-title":"Br J Haematol"},{"issue":"1","key":"2708_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1172\/JCI83013","volume":"126","author":"C Bologna","year":"2016","unstructured":"Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, Pagnani A, Coscia M, D\u2019Arena G, Mereu E, et al. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. J Clin Invest. 2016;126(1):181\u201394.","journal-title":"J Clin Invest"},{"issue":"4","key":"2708_CR58","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1593\/neo.91972","volume":"12","author":"RK Gandhirajan","year":"2010","unstructured":"Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlosser A, Schmitt EK, Hallek M, Kreuzer KA. Small molecule inhibitors of Wnt\/beta-catenin\/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia. 2010;12(4):326\u201335.","journal-title":"Neoplasia"},{"issue":"7","key":"2708_CR59","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood-2014-01-552067","volume":"124","author":"L Wang","year":"2014","unstructured":"Wang L, Shalek AK, Lawrence M, Ding R, Gaublomme JT, Pochet N, Stojanov P, Sougnez C, Shukla SA, Stevenson KE, et al. Somatic mutation as a mechanism of Wnt\/beta-catenin pathway activation in CLL. Blood. 2014;124(7):1089\u201398.","journal-title":"Blood"},{"issue":"1","key":"2708_CR60","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1038\/s41467-018-06069-5","volume":"9","author":"M Mangolini","year":"2018","unstructured":"Mangolini M, Gotte F, Moore A, Ammon T, Oelsner M, Lutzny-Geier G, Klein-Hitpass L, Williamson JC, Lehner PJ, Durig J, et al. Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia. Nat Commun. 2018;9(1):3839.","journal-title":"Nat Commun"},{"issue":"1","key":"2708_CR61","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2007-07-102350","volume":"111","author":"X Du","year":"2008","unstructured":"Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood. 2008;111(1):338\u201343.","journal-title":"Blood"},{"issue":"9","key":"2708_CR62","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/ijc.23751","volume":"123","author":"T Kazemi","year":"2008","unstructured":"Kazemi T, Asgarian-Omran H, Hojjat-Farsangi M, Shabani M, Memarian A, Sharifian RA, Razavi SM, Jeddi-Tehrani M, Rabbani H, Shokri F. Fc receptor-like 1\u20135 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. Int J Cancer. 2008;123(9):2113\u20139.","journal-title":"Int J Cancer"},{"issue":"5","key":"2708_CR63","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/leu.2012.329","volume":"27","author":"DE Spaner","year":"2013","unstructured":"Spaner DE, Lee E, Shi Y, Wen F, Li Y, Tung S, McCaw L, Wong K, Gary-Gouy H, Dalloul A, et al. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia. 2013;27(5):1090\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"2708_CR64","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1182\/blood-2004-08-3344","volume":"106","author":"P Oppezzo","year":"2005","unstructured":"Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, Kimura EY, Bechet S, Dumas G, Brissard M, et al. The LPL\/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood. 2005;106(2):650\u20137.","journal-title":"Blood"},{"issue":"15","key":"2708_CR65","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1182\/blood-2010-09-304881","volume":"117","author":"H Duzkale","year":"2011","unstructured":"Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O\u2019Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, et al. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood. 2011;117(15):4076\u201384.","journal-title":"Blood"},{"issue":"1","key":"2708_CR66","first-page":"56","volume":"91","author":"MB Veer","year":"2006","unstructured":"Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ, Lom K, Valk PJ. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica. 2006;91(1):56\u201363.","journal-title":"Haematologica"},{"issue":"21","key":"2708_CR67","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019003453","volume":"135","author":"A Condoluci","year":"2020","unstructured":"Condoluci A, Terzidi Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859\u201369.","journal-title":"Blood"},{"issue":"3","key":"2708_CR68","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3324\/haematol.2018.196931","volume":"104","author":"N Gimenez","year":"2019","unstructured":"Gimenez N, Martinez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, et al. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica. 2019;104(3):576\u201386.","journal-title":"Haematologica"},{"issue":"42","key":"2708_CR69","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/onc.2014.450","volume":"34","author":"D Kern","year":"2015","unstructured":"Kern D, Regl G, Hofbauer SW, Altenhofer P, Achatz G, Dlugosz A, Schnidar H, Greil R, Hartmann TN, Aberger F. Hedgehog\/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. Oncogene. 2015;34(42):5341\u201351.","journal-title":"Oncogene"},{"issue":"12","key":"2708_CR70","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/1541-7786.MCR-08-0142","volume":"6","author":"GV Hegde","year":"2008","unstructured":"Hegde GV, Peterson KJ, Emanuel K, Mittal AK, Joshi AD, Dickinson JD, Kollessery GJ, Bociek RG, Bierman P, Vose JM, et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Mol Cancer Res. 2008;6(12):1928\u201336.","journal-title":"Mol Cancer Res"},{"issue":"25","key":"2708_CR71","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1182\/blood-2018-09-873695","volume":"133","author":"EM Ghia","year":"2019","unstructured":"Ghia EM, Rassenti LZ, Neuberg DS, Blanco A, Yousif F, Smith EN, McPherson JD, Hudson TJ, Harismendy O, et al. Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. Blood. 2019;133(25):2651\u201363.","journal-title":"Blood"},{"issue":"7","key":"2708_CR72","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/annonc\/mdw138","volume":"27","author":"R Houot","year":"2016","unstructured":"Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, Bouabdallah K, Morschhauser F, Le Gouill S, Salles GA, et al. Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. Ann Oncol. 2016;27(7):1349\u201350.","journal-title":"Ann Oncol"},{"issue":"24","key":"2708_CR73","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1182\/blood-2013-10-534073","volume":"123","author":"U Rozovski","year":"2014","unstructured":"Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O\u2019Brien S, Jain N, et al. Stimulation of the B-cell receptor activates the JAK2\/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014;123(24):3797\u2013802.","journal-title":"Blood"},{"issue":"10","key":"2708_CR74","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/ijc.30892","volume":"141","author":"U Rozovski","year":"2017","unstructured":"Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, et al. Activation of the B-cell receptor successively activates NF-kappaB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017;141(10):2076\u201381.","journal-title":"Int J Cancer"},{"key":"2708_CR75","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers11121939","volume":"11","author":"F Severin","year":"2019","unstructured":"Severin F, Frezzato F, Visentin A, Martini V, Trimarco V, Carraro S, Tibaldi E, Brunati AM, Piazza F, Semenzato G, et al. In chronic lymphocytic leukemia the JAK2\/STAT3 pathway is constitutively activated and its inhibition leads to CLL cell death unaffected by the protective bone marrow microenvironment. Cancers. 2019;11:12.","journal-title":"Cancers"},{"issue":"1","key":"2708_CR76","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2011-07-370403","volume":"119","author":"S Krysov","year":"2012","unstructured":"Krysov S, Dias S, Paterson A, Mockridge CI, Potter KN, Smith KA, Ashton-Key M, Stevenson FK, Packham G. Surface IgM stimulation induces MEK1\/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood. 2012;119(1):170\u20139.","journal-title":"Blood"},{"issue":"4","key":"2708_CR77","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2015-07-660969","volume":"127","author":"A Yeomans","year":"2016","unstructured":"Yeomans A, Thirdborough SM, Valle-Argos B, Linley A, Krysov S, Hidalgo MS, Leonard E, Ishfaq M, Wagner SD, Willis AE, et al. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Blood. 2016;127(4):449\u201357.","journal-title":"Blood"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02708-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-021-02708-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02708-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T10:05:10Z","timestamp":1611396310000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-02708-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2708"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-02708-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"15 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study does not involve animal and\/or human tissue\/individual data\/ participants, there is no ethics related issues. No permissions were required to use any repository data involved in the present study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}